Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Bipartisan RheumPAC Serves Needs of Patients and Rheumatologists

Kelly Tyrrell  |  October 5, 2016

For more than a decade, the ACR’s Government Affairs Committee (GAC) has given rheumatologists a voice in the halls of Congress. Since 2007, that voice has been amplified by RheumPAC, the bipartisan political action committee for ACR/ARHP members that helps advance the policy goals of the College, rheumatology professionals and their patients. “RheumPAC allows us…

New Kits Address Pediatric-to-Adult-Care Transition

Kurt Ullman  |  October 5, 2016

The transition from pediatric to adult care can be a rocky one. For many rheumatology patients, any problems in the move can cause gaps in care. To address this issue, the American College of Rheumatology (ACR) joined the American College of Physicians’ (ACP) Pediatric to Adult Care Transitions Initiative. The Initiative is a project spearheaded…

Advocates on the Hill

Kelly Tyrrell  |  October 5, 2016

On Sept. 12–13, nearly 100 rheumatologists, health professionals and patients participated in the Advocates for Arthritis event on Capitol Hill to advocate on behalf of those living with and treating rheumatic diseases. Key Requests & Congressional Support Attendees visited 116 members of Congress and their staff members to: Advocate for changes to the Centers for…

How to Document E/M Services

Kimberly Retzlaff  |  October 5, 2016

Documenting evaluation and management (E/M) services involves many factors, and it’s important to code to the most appropriate level of service to avoid compliance risks. To assist providers with documentation, the Centers for Medicare & Medicaid Services (CMS) provides its 1995 and 1997 Documentation Guidelines for Evaluation and Management Services. For billing purposes, either version…

FDA Update: New Boxed Warnings for Opioids & Benzodiazepines; Plus New Drug Safety Labeling Changes Database

Michele B. Kaufman, PharmD, BCGP  |  October 5, 2016

Due to serious side effects from the combined use of opioids and benzodiazepines, the FDA has issued boxed warnings for both types of medication…

Tenet Healthcare to Pay More Than $513 Million in Fraud Scheme

Reuters Staff  |  October 4, 2016

WASHINGTON (Reuters)—U.S. hospital chain Tenet Healthcare Corp. and two of its Atlanta-area units will pay more than $513 million to resolve criminal charges and civil claims relating to a scheme to defraud the U.S. and pay kickbacks in exchange for patient referrals, the U.S. Department of Justice said on Monday.1 Tenet had disclosed in August…

Big Pharma vs. Big Pharma in Court Battles over Biosimilar Drugs

John Miller  |  October 4, 2016

ZURICH (Reuters)—The line dividing makers of brand-name drugs and copycat medicines is blurring as companies known for innovative treatments queue up to peddle copies of rivals’ complex biological medicines. These drug makers are now increasingly straddling both sides of the courtroom, too, protecting their high-price products from biosimilars—biopharmaceutical drugs with the treatment properties of medicines…

Anti-TNFs in Early Puberty May Improve Growth in Pediatric IBD

Reuters Staff  |  October 4, 2016

NEW YORK (Reuters Health)—Anti-TNF drugs are more likely to improve growth in children with inflammatory bowel disease (IBD) if they’re given in the earlier stages of puberty, new findings show.¹ Children who achieve remission are also more likely to have satisfactory growth, the research team reported online on Sept. 21 in the Journal of Pediatric…

Do RA Patients in Clinical Trials for Biologics Represent the Average?

Arthritis Care & Research  |  October 4, 2016

It’s estimated that a majority of patients with rheumatoid arthritis (RA) have been exposed to biologic treatments. However, the randomized controlled trials demonstrating the safety and efficacy of these biologic agents have strict participant eligibility requirements. New research has examined the requirements of 30 trials for biologics and applied those standards to two large clinical cohorts. The result: A majority of these RA patients did not satisfy the criteria…

The Role of Benign Joint Hypermobility in Functional Pain Disorders

Lara C. Pullen, PhD  |  October 3, 2016

Physicians have been puzzled by the role of benign joint hypermobility syndrome in the development of gastrointestinal disorders and other autonomic symptoms and co-morbidities. However, new research found that benign joint hypermobility syndrome only minimally affects autonomic abnormalities…

  • « Previous Page
  • 1
  • …
  • 481
  • 482
  • 483
  • 484
  • 485
  • …
  • 821
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences